Amylyx Pharmaceuticals reported a net loss of $41.4 million for Q2 2025, an improvement from the $72.7 million net loss in Q2 2024. The company had no product revenue for the quarter. Research and development expenses increased, while selling, general, and administrative expenses decreased. The company maintains a strong cash position of $180.8 million, with a cash runway expected through the end of 2026.

Amylyx Pharmaceuticals reported a net loss of $35.9 million for the first quarter of 2025, a significant improvement compared to the $118.8 million net loss in the same period last year. The company's cash position strengthened to $204.1 million, extending its expected cash runway through the end of 2026. The quarter saw continued progress in clinical trials, particularly the pivotal Phase 3 LUCIDITY trial for avexitide in PBH and the initiation of the Phase 1 LUMINA trial for AMX0114 in ALS.

Amylyx Pharmaceuticals reported a net loss of $37.5 million for the fourth quarter of 2024, compared to a net income of $4.7 million for the same period in 2023. The company highlighted progress in its pipeline development, including the initiation of a pivotal Phase 3 trial for avexitide and the advancement of other programs in Wolfram syndrome, PSP, and ALS. A public offering extended the company's cash runway through the end of 2026.

Amylyx Pharmaceuticals reported a net product revenue of $0.4 million, which was related to adjustments to the Company’s gross-to-net accrual estimates for prior period sales of RELYVRIO® and ALBRIOZA™. The company's cash, cash equivalents, and marketable securities totaled $234.4 million, with a cash runway expected into 2026. A net loss of $72.7 million, or $1.07 per share, was reported for the quarter.

Amylyx Pharmaceuticals reported a net product revenue of $(1.0) million for Q2 2024, a significant decrease compared to $98.2 million in the same period of 2023. The company experienced a net loss of $72.7 million, or $1.07 per share, compared to a net income of $22.1 million, or $0.31 per diluted share, for the same period in 2023. However, the company acquired avexitide, a Phase 3-ready GLP-1 receptor antagonist, and is advancing its pipeline with multiple clinical trials planned.

Amylyx Pharmaceuticals reported a net product revenue of $88.6 million for the first quarter of 2024, compared to $71.4 million for the same period in 2023. However, the company experienced a net loss of $118.8 million, or $1.75 per share, compared to a net income of $1.6 million, or $0.02 per share, for the same period in 2023. The company is focusing on key clinical programs and has a cash runway into 2026.

Amylyx Pharmaceuticals reported Q4 2023 financial results, highlighted by $108.4 million in net product revenue and a net income of $4.7 million. The company's full-year revenue reached $380.8 million, with a net income of $49.3 million. Amylyx is progressing its clinical trials and expanding the commercialization of its ALS treatments.

Amylyx Pharmaceuticals reported a successful third quarter in 2023, marked by $102.7 million in product revenue and a net income of $20.9 million. The company's financial position remains strong, supported by cash, cash equivalents, and short-term investments totaling $355.0 million.

Amylyx Pharmaceuticals reported strong financial results for the second quarter of 2023, with product revenue of $98.2 million and net income of $22.1 million. The company's commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada continued to progress.

Amylyx Pharmaceuticals reported a net product revenue of $71.4 million for the first quarter of 2023, driven by the commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada. The company's net income for the quarter was $1.6 million, a significant improvement compared to the net loss of $47.8 million in the same period of 2022.

Amylyx Pharmaceuticals reported Q4 2022 financial results, featuring net product revenue of $21.9 million and a net loss of $42.7 million, or $0.65 per share. The company's commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada are progressing, and they appointed Karen Firestone to the Board of Directors.

Amylyx Pharmaceuticals reported a net loss of $47.8 million for the first quarter of 2022. The company is focused on commercial launch readiness to support AMX0035 for ALS treatment and engaging with regulators for potential approvals.